The CPLX1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-mediated gene disruption model targeting the CPLX1 locus in a polyclonal Raji cell population. This polyclonal knockout product avoids clonal selection, maintaining cellular heterogeneity while achieving loss of complexin-1 function across the bulk culture. Derived from the human B lymphocyte Raji line, these cells provide a physiologically relevant platform for examining complexin-1 biology in a non-neuronal background. The genetic disruption is introduced via nucleofection of ribonucleoprotein complexes, generating a heterogeneous knockout pool suitable for pooled screening and population-level analyses.
The Raji host cell line is a widely utilized lymphoblastoid model derived from a Burkitt lymphoma patient, characterized by Epstein-Barr virus (EBV) positivity and continuous proliferation. As B lymphocytes, Raji cells are integral to adaptive immunity, capable of antibody production and antigen presentation. Their robust exocytic machinery and secretory pathways make them particularly valuable for studying SNARE-mediated membrane fusion events, even though complexin-1 is traditionally associated with neuronal synapses. The lymphoblastoid phenotype offers ease of culture and genetic manipulation, facilitating rapid generation of gene-edited derivatives for functional genomics.
CPLX1 encodes complexin-1, a cytosolic protein that directly binds assembled SNARE complexes composed of Syntaxin-1, SNAP-25, and VAMP2, and interacts with Synaptotagmin to regulate Ca2?-triggered exocytosis. Mechanistically, complexin-1 serves as a molecular clamp, inhibiting spontaneous synaptic vesicle fusion while synchronizing rapid neurotransmitter release in response to Ca2? influx. This protein functions within the broader synaptic vesicle cycle pathway, interacting with representative components such as Munc18, NSF, and SNAPs. Upstream, complexin-1 activity is modulated by neuronal activity and intracellular Ca2? levels; downstream, it controls synaptic vesicle fusion and neurotransmitter secretion. Although best characterized in neurons, expression of CPLX1 in lymphoid cells suggests roles in regulated secretion pathways beyond the synapse.
In the Raji B lymphocyte context, the CPLX1 knockout model allows researchers to probe non-canonical functions of complexin-1 in adaptive immunity. B cells rely on SNARE-mediated vesicle trafficking for surface receptor presentation, cytokine secretion, and antibody release, processes potentially influenced by complexin-1. Disruption of CPLX1 may alter exocytic dynamics, impacting pathways relevant to immune synapse formation or antigen processing. Given the association of CPLX1 mutations with neurological disorders such as epilepsy and schizophrenia, this model also supports cross-tissue investigation into fundamental SNARE machinery dysfunction, offering a simplified cellular system to complement neuronal studies.
This polyclonal knockout product is designed for advanced applications including mechanistic dissection of exocytosis using secretion assays (ELISA), quantification of SNARE complex integrity via co-immunoprecipitation, and visualization of complexin-1 localization by immunofluorescence. Flow cytometry and Western blotting enable confirmation of protein loss, while RT-qPCR validates transcript depletion. Researchers can employ these cells to screen small molecules that modulate SNARE function or to model complexin-1-related neuropathology in a proliferative host. Further technical details and support are available from Ascent Research.
